Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Beijing Youcare Kechuang Pharmaceutical Technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and Japan registers with Beijing Youcare Kechuang Pharmaceutical Technology as lead sponsor. Synced 11 Nov 2026
5Current trials
3Recruiting now
0Drugs in these trials
2Trial registers
At a glance

Beijing Youcare Kechuang Pharmaceutical Technology is the lead sponsor of 5 current clinical trials in our China and Japan registers. 3 are recruiting patients now. The most common phase is Phase 1. The most-studied condition is Respiratory Syncytial Virus (RSV).

ClinicalTrials.gov trials by status

  • Recruiting360%
  • Not yet open240%

Trials by phase

  • Phase 1360%
  • Phase 2240%
01

Clinical trials sponsored by Beijing Youcare Kechuang Pharmaceutical Technology

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection
NCT07786779 · ClinicalTrials.gov ↗ · Venous Thromboembolism (VTE)
Phase 1 Recruiting 2026-07 China
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
NCT07694557 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus (RSV)
Phase 1 Recruiting 2026-07 China
Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors
NCT07631793 · ClinicalTrials.gov ↗ · Malignant Neoplasms
Phase 1 Recruiting 2026-03 China
A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation Solution
NCT07808268 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus (RSV)
Phase 2 Not yet open 2026-10 China, Japan
Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)
NCT07914660 · ClinicalTrials.gov ↗ · Hyperlipoproteinemia (a)
Phase 2 Not yet open 2026-11 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Beijing Youcare Kechuang Pharmaceutical Technology trials

4 conditions
Respiratory Syncytial Virus (RSV)2Hyperlipoproteinemia (a)1Venous Thromboembolism (VTE)1Malignant Neoplasms1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China53
Clinical trials in Japan10

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Respiratory Syncytial Virus (RSV)

SponsorTrials
MAXVAX Biotechnology Limited Liability Company3
Shanghai Institute Of Biological Products2
Guangzhou Patronus Biotech2
Immorna Biotherapeutics1
Menzies School of Health Research1

Sponsors with the most current trials registered for this condition.

05

Questions about Beijing Youcare Kechuang Pharmaceutical Technology trials

How many clinical trials does Beijing Youcare Kechuang Pharmaceutical Technology sponsor?

Beijing Youcare Kechuang Pharmaceutical Technology is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China and Japan registers, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.

Are Beijing Youcare Kechuang Pharmaceutical Technology trials recruiting?

Yes. 3 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.